Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Blueprint Medicines Corporation develops and distributes biomedical treatments. The Company researches and produces medicines and treatments for cancer targeting the molecular differences. Blueprint Medicines focuses selective drugs for genomically defined cancer patients.
Website: blueprintmedicines.com



Growth: Good revenue growth rate 55.2%, there is slowdown compared to average historical growth rates 62.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -27.8%. On average the margin is improving steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.08 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -2.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 241.0% higher than minimum and 0.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.2x by EV / Sales multiple , the company can be 76.0% overvalued

Insiders: For the last 3 months insiders sold company shares on $1.9 mln (-0.029% of cap.)

Key Financials (Download financials)

Ticker: BPMC
Share price, USD:  (0.0%)129.46
year average price 98.94  


year start price 112.19 2024-07-27

min close price 79.22 2025-04-08

max close price 129.46 2025-07-17

current price 129.46 2025-07-26
Common stocks: 59 570 497

Dividend Yield:  0.0%
EV / Sales: 13.6x
Margin (EBITDA LTM / Revenue): -27.8%
Fundamental value created in LTM:
Market Cap ($m): 7 712
Net Debt ($m): -110
EV (Enterprise Value): 7 602
Price to Book: 24.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-14globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)

2025-06-12prnewswire.com

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

2025-06-02globenewswire.com

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

2025-06-02barrons.com

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

2025-05-01seekingalpha.com

Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript

2025-04-07seekingalpha.com

Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth

2025-02-14zacks.com

BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline

2025-02-13seekingalpha.com

Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript

2025-02-13zacks.com

Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates

2025-02-06zacks.com

Should You Buy Blueprint Medicines (BPMC) After Golden Cross?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-30 2024-08-01 2024-05-02 2024-02-15 2023-10-26 2023-08-02 2023-05-04 2023-02-16 2022-11-01
acceptedDate 2024-10-30 16:27:49 2024-08-01 16:48:17 2024-05-02 16:43:51 2024-02-15 17:26:31 2023-10-26 16:01:57 2023-08-02 16:02:22 2023-05-04 16:23:29 2023-02-16 17:24:10 2022-11-01 16:18:43
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 128M 138M 96M 72M 57M 58M 63M 39M 66M
costOfRevenue 2M 11M 8M 2M 5M 2M 3M 5M 3M
grossProfit 126M 127M 88M 70M 52M 55M 60M 34M 63M
grossProfitRatio 0.985 0.919 0.917 0.975 0.92 0.96 0.95 0.875 0.955
researchAndDevelopmentExpenses 85M 81M 83M 96M 110M 110M 112M 118M 128M
generalAndAdministrativeExpenses 63M 67M 67M 62M 58M 53M 0 0 0
sellingAndMarketingExpenses 27M 23M 17M 17M 13M 19M 0 0 0
sellingGeneralAndAdministrativeExpenses 90M 89M 84M 79M 71M 72M 71M 64M 58M
otherExpenses 0 -1000 376 000 -577 000 -728 000 -626 000 1M 2M 2M
operatingExpenses 175M 170M 167M 175M 181M 183M 184M 184M 187M
costAndExpenses 177M 181M 175M 177M 186M 186M 187M 189M 190M
interestIncome 11M 10M 9M 10M 9M 8M 0 -869 000 0
interestExpense 19M 17M 15M 15M -4M -4M 6M 24M -8M
depreciationAndAmortization 4M 4M 5M 43 812 3M 4M 12M 7M 2M
ebitda -33M -29M -74M -104M -129M -128M -123M -150M -123M
ebitdaratio -0.26 -0.285 -0.77 -1.439 -2.28 -2.223 -1.947 -3.863 -1.859
operatingIncome -49M -43M -79M -105M -129M -128M -135M -157M -124M
operatingIncomeRatio -0.382 -0.312 -0.82 -1.461 -2.28 -2.223 -2.139 -4.044 -1.884
totalOtherIncomeExpensesNet -7M -7M 168M -6M -5M -626 000 6M -789 000 -8M
incomeBeforeTax -56M -50M 89M -111M -134M -133M -129M -158M -132M
incomeBeforeTaxRatio -0.437 -0.361 0.929 -1.541 -2.36 -2.303 -2.039 -4.064 -2.005
incomeTaxExpense 273 000 102 000 180 000 61 000 197 000 190 000 520 000 1M 886 000
netIncome -56M -50M 89M -111M -134M -133M -130M -159M -133M
netIncomeRatio -0.439 -0.362 0.927 -1.541 -2.364 -2.307 -2.047 -4.091 -2.018
eps -0.89 -0.8 1.45 -1.82 -2.2 -2.19 -2.15 -2.65 -2.23
epsdiluted -0.89 -0.8 1.4 -1.82 -2.2 -2.19 -2.15 -2.65 -2.23
weightedAverageShsOut 63M 63M 62M 61M 61M 61M 60M 60M 60M
weightedAverageShsOutDil 63M 63M 64M 61M 61M 61M 60M 60M 60M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-30 2024-08-01 2024-05-02 2024-02-15 2023-10-26 2023-08-02 2023-05-04 2023-02-16 2022-11-01
acceptedDate 2024-10-30 16:27:49 2024-08-01 16:48:17 2024-05-02 16:43:51 2024-02-15 17:26:31 2023-10-26 16:01:57 2023-08-02 16:02:22 2023-05-04 16:23:29 2023-02-16 17:24:10 2022-11-01 16:18:43
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 89M 55M 113M 71M 56M 76M 170M 120M 291M
shortTermInvestments 645M 709M 535M 639M 657M 647M 652M 825M 846M
cashAndShortTermInvestments 734M 764M 648M 711M 827M 837M 961M 1 078M 1 137M
netReceivables 66M 85M 60M 43M 41M 38M 31M 37M 22M
inventory 13M 15M 31M 21M 16M 17M 18M 30M 35M
otherCurrentAssets 42M 40M 38M 33M 37M 33M 731M 35M 34M
totalCurrentAssets 855M 904M 777M 808M 808M 811M 900M 1 047M 1 228M
propertyPlantEquipmentNet 104M 109M 113M 116M 116M 114M 113M 115M 117M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 143M 126M 95M 142M 142M 167M 161M 83M
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 241M 48M 23M 31M 39M 39M 40M 27M 30M
totalNonCurrentAssets 345M 300M 262M 241M 297M 295M 320M 303M 231M
otherAssets 0 1 0 1 0 0 0 0 0
totalAssets 1 200M 1 204M 1 038M 1 049M 1 105M 1 106M 1 220M 1 350M 1 458M
accountPayables 5M 5M 5M 5M 7M 7M 11M 3M 4M
shortTermDebt 58M 127M 87M 81M 42M 29M 28M 27M 25M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 64M 4M 7M 812 000 448M 446M 443M 449M 25M
otherCurrentLiabilities 131M 108M 107M 128M -300M -313M -309M -296M 121M
totalCurrentLiabilities 258M 244M 207M 215M 197M 169M 173M 183M 176M
longTermDebt 413M 626M 432M 611M 84M 87M 90M 215M 219M
deferredRevenueNonCurrent 8M 8M 5M 5M 5M 5M 5M 427M 415M
deferredTaxLiabilitiesNonCurrent 0 75M 78M 82M 0 0 0 0 0
otherNonCurrentLiabilities 207M 6M 6M 6M 616M 534M 538M 10M 588M
totalNonCurrentLiabilities 629M 640M 521M 704M 705M 626M 633M 652M 643M
otherLiabilities 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 85M 88M 78M 82M 96M 98M 101M 103M 106M
totalLiabilities 887M 883M 728M 919M 903M 795M 806M 835M 818M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 63 000 63 000 63 000 61 000 61 000 61 000 60 000 60 000 60 000
retainedEarnings -2 357M -2 301M -2 251M -2 340M -2 229M -2 095M -1 963M -1 833M -1 674M
accumulatedOtherComprehensiveIncomeLoss -1M -4M -4M -3M -3M -4M -5M -10M -15M
othertotalStockholdersEquity 2 671M 2 625M 2 565M 2 474M 2 434M 2 411M 2 381M 2 358M 2 329M
totalStockholdersEquity 313M 320M 311M 131M 203M 311M 414M 515M 640M
totalEquity 313M 320M 311M 131M 203M 311M 414M 515M 640M
totalLiabilitiesAndStockholdersEquity 1 200M 1 204M 1 038M 1 049M 1 105M 1 106M 1 220M 1 350M 1 458M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 200M 1 204M 1 038M 1 049M 1 105M 1 106M 1 220M 1 350M 1 458M
totalInvestments 645M 852M 661M 734M 657M 647M 652M 959M 929M
totalDebt 471M 740M 598M 774M 126M 116M 118M 242M 244M
netDebt 382M 686M 485M 703M 70M 41M -52M 123M -47M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-10-30 2024-08-01 2024-05-02 2024-02-15 2023-10-26 2023-08-02 2023-05-04 2023-02-16 2022-11-01
acceptedDate 2024-10-30 16:27:49 2024-08-01 16:48:17 2024-05-02 16:43:51 2024-02-15 17:26:31 2023-10-26 16:01:57 2023-08-02 16:02:22 2023-05-04 16:23:29 2023-02-16 17:24:10 2022-11-01 16:18:43
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -56M -50M 89M -111M -134M -133M -130M -159M -133M
depreciationAndAmortization 4M 4M 5M 2M 3M 4M 4M 7M 2M
deferredIncomeTax 0 0 0 -29M -12M 0 0 0 0
stockBasedCompensation 28M 28M 24M 23M 23M 24M 23M 26M 24M
changeInWorkingCapital 15M -27M -43M 10M 3M -28M -26M -6M -6M
accountsReceivables 20M -25M -17M -2M -6M -8M -5M -4M 8M
inventory -4M -5M 3M 829 000 3M -8M 78 000 12M -6M
accountsPayables 3M -82 000 313 000 -2M 26 000 -4M 8M -4M -9M
otherWorkingCapital -4M 3M -29M 14M 6M -8M -29M -10M 1M
otherNonCashItems -5M -3M -128M 26M 12M 3M 6M 10M -17M
netCashProvidedByOperatingActivities -14M -48M -102M -79M -104M -130M -123M -121M -130M
investmentsInPropertyPlantAndEquipment -25 000 -3M -1M -5M -6M -3M -3M -1M -4M
acquisitionsNet 0 0 0 -83M 3M 0 0 0 0
purchasesOfInvestments -201M -355M -200M -118M -241M -275M -133M -231M -219M
salesMaturitiesOfInvestments 231M 170M 278M 201M 238M 310M 308M 179M 91M
otherInvestingActivites 0 0 78M 83M -3M 0 0 -1000 -289 000
netCashUsedForInvestingActivites 30M -188M 77M 79M -10M 32M 173M -53M -132M
debtRepayment 0 147M -369 000 -35 000 -98M 0 0 0 0
commonStockIssued -99M 31M 67M 16M 431 000 5M 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 18M 31M -369 000 -44 000 196M 0 0 2M 381M
netCashUsedProvidedByFinancingActivities 18M 178M 67M 16M 98M 5M 0 2M 381M
effectOfForexChangesOnCash 591 000 -31 000 -145 000 487 000 -541 000 59 000 197 000 478 000 -379 000
netChangeInCash 46M -59M 42M 15M -16M -93M 50M -172M 118M
cashAtEndOfPeriod 101M 55M 113M 71M 66M 82M 175M 125M 297M
cashAtBeginningOfPeriod 55M 113M 71M 56M 82M 175M 125M 297M 179M
operatingCashFlow -14M -48M -102M -79M -104M -130M -123M -121M -130M
capitalExpenditure -25 000 -3M -1M -5M -6M -3M -3M -1M -4M
freeCashFlow -14M -51M -103M -84M -111M -133M -126M -123M -134M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-30 11:00 ET
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
2024-10-16 12:00 ET
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
2024-09-10 12:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2024-08-01 11:00 ET
Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
2024-07-18 12:00 ET
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
2024-05-30 22:01 ET
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
2024-05-23 21:05 ET
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
2024-05-06 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-02 11:00 ET
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
2024-04-18 12:00 ET
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
2024-04-11 12:00 ET
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
2024-04-04 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-06 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-23 13:00 ET
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
2024-02-15 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
2024-02-05 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 13:00 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
2024-01-08 13:00 ET
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-05 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-18 13:00 ET
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 13:05 ET
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
2023-12-09 17:30 ET
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
2023-12-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-28 13:00 ET
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
2023-11-10 13:00 ET
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
2023-11-03 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-26 11:00 ET
Blueprint Medicines Reports Third Quarter 2023 Results
2023-10-12 12:00 ET
Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
2023-10-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-04 20:16 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-02 11:00 ET
Blueprint Medicines Reports Second Quarter 2023 Results
2023-07-19 12:00 ET
Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023
2023-07-05 20:30 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-05 21:00 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-03 13:00 ET
Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting
2023-05-23 14:00 ET
NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis
2023-05-22 20:04 ET
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
2023-05-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-04 11:00 ET
Blueprint Medicines Reports First Quarter 2023 Results
2023-04-26 14:00 ET
Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting
2023-04-20 20:01 ET
Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
2023-04-11 12:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2023-04-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-28 20:05 ET
Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222
2023-03-07 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-26 20:00 ET
Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
2023-02-23 13:00 ET
Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche
2023-02-16 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
2023-02-10 13:00 ET
Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
2023-02-09 13:00 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
2023-02-07 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-03 14:00 ET
Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
2023-01-23 13:00 ET
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
2023-01-06 14:00 ET
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
2023-01-05 13:00 ET
Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale
2023-01-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-12-11 22:30 ET
Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis
2022-12-05 22:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-22 21:36 ET
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
2022-11-09 21:01 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2022-11-04 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-03 13:00 ET
Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting
2022-11-01 12:00 ET
Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022
2022-10-19 12:00 ET
Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Results on November 1, 2022
2022-10-06 20:30 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-06 20:01 ET
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-24 12:00 ET
CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis
2022-08-17 11:00 ET
Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints
2022-08-04 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-08-02 11:00 ET
Blueprint Medicines Reports Second Quarter 2022 Results
2022-07-26 12:00 ET
Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
2022-07-14 20:15 ET
Blueprint Medicines Publishes Inaugural Corporate Responsibility Report
2022-07-07 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-06-30 11:30 ET
Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million
2022-06-30 11:15 ET
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
2022-06-23 20:26 ET
Blueprint Medicines Appoints Habib Dable to its Board of Directors
2022-06-09 11:00 ET
Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis
2022-06-03 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-05-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-05-03 11:00 ET
Blueprint Medicines Reports First Quarter 2022 Results
2022-04-26 12:00 ET
Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
2022-04-08 17:00 ET
Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer
2022-04-06 20:00 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-03-25 14:15 ET
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis
2022-03-08 21:30 ET
Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022
2022-03-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-02-28 13:00 ET
Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies
2022-02-16 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results
2022-02-11 21:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2022-02-09 13:00 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022
2022-02-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-01-28 13:00 ET
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
2022-01-20 13:00 ET
Blueprint Medicines Elevates Two Talented Leaders to its Executive Team
2022-01-10 13:00 ET
Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership
2022-01-06 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-01-05 13:00 ET
Blueprint Medicines Announces CEO and Leadership Transition Plan
2021-12-30 13:51 ET
Blueprint Medicines Completes Acquisition of Lengo Therapeutics
2021-12-09 21:01 ET
Blueprint Medicines Appoints Daniella Beckman to its Board of Directors
2021-12-07 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-12-06 21:01 ET
Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT® (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis
2021-11-29 12:00 ET
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
2021-11-09 13:00 ET
Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
2021-11-09 13:00 ET
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
2021-11-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-10-28 11:00 ET
Blueprint Medicines Reports Third Quarter 2021 Financial Results
2021-10-21 12:00 ET
Blueprint Medicines to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
2021-10-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-09-03 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-09-02 12:00 ET
Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-04 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-07-29 11:00 ET
Blueprint Medicines Reports Second Quarter 2021 Financial Results
2021-07-28 12:00 ET
MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development
2021-07-22 12:00 ET
Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
2021-07-07 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-06-16 19:50 ET
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
2021-06-04 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-05-25 12:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2021-05-19 21:00 ET
Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
2021-05-17 12:00 ET
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
2021-05-05 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-04-29 11:00 ET
Blueprint Medicines Reports First Quarter 2021 Financial Results
2021-04-22 12:00 ET
Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
2021-04-11 18:00 ET
Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021
2021-04-10 12:30 ET
Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021
2021-04-07 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-04-05 12:00 ET
Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021
2021-03-10 21:30 ET
Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021
2021-03-05 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-03-03 13:00 ET
Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
2021-02-17 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-10 13:00 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021
2021-02-05 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-01-11 13:05 ET
Blueprint Medicines Announces R&D Leadership Transitions
2021-01-11 13:00 ET
Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadership
2021-01-05 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-12-17 13:00 ET
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
2020-12-07 13:00 ET
Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis
2020-12-04 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-12-01 20:15 ET
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
2020-11-23 13:00 ET
Blueprint Medicines To Present Broad Range of Data Reinforcing Commitment to Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition
2020-11-03 21:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-10-29 11:00 ET
Blueprint Medicines Reports Third Quarter 2020 Financial Results
2020-10-22 12:00 ET
Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
2020-10-02 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-09-25 15:46 ET
Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
2020-09-22 11:00 ET
Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Patients with Advanced Systemic Mastocytosis
2020-09-20 12:25 ET
Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO™ (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Cancer
2020-09-17 12:00 ET
Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020
2020-09-09 20:01 ET
Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare Conference
2020-09-04 23:00 ET
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
2020-09-04 12:00 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-09-01 12:00 ET
Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
2020-08-19 01:27 ET
CStone Pharmaceuticals Reports Financial Results for the First Half of 2020
2020-08-04 12:00 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-07-30 11:00 ET
Blueprint Medicines Reports Second Quarter 2020 Financial Results
2020-07-24 12:30 ET
Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
2020-07-23 12:00 ET
Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020
2020-07-14 05:00 ET
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
2020-07-02 20:01 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-07-01 12:00 ET
Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
2020-06-29 22:30 ET
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST
2020-06-06 13:00 ET
Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic Mastocytosis
2020-06-03 12:00 ET
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-05-29 12:00 ET
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
2020-05-27 20:30 ET
Blueprint Medicines to Present at Upcoming Investors Conferences
2020-05-26 12:00 ET
Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020
2020-05-15 12:00 ET
Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
2020-05-14 13:00 ET
Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs
2020-05-06 11:00 ET
Blueprint Medicines Reports First Quarter 2020 Financial Results
2020-04-29 12:00 ET
Blueprint Medicines to Report First Quarter 2020 Financial Results on Wednesday, May 6, 2020
2020-04-28 11:00 ET
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
2020-04-01 12:00 ET
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
2020-03-16 11:00 ET
Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis
2020-03-09 13:00 ET
Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on Monday, March 16, 2020
2020-02-24 21:05 ET
Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 2020 AAAAI Annual Meeting
2020-02-19 13:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences
2020-02-13 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-06 21:05 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020
2020-02-06 13:00 ET
Blueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with Fourth-Line Gastrointestinal Stromal Tumor
2020-01-23 03:24 ET
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
2020-01-21 21:01 ET
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
2020-01-08 13:00 ET
Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer
2020-01-06 13:00 ET
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
2019-12-08 14:00 ET
Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested
2019-11-14 13:00 ET
Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference
2019-11-06 14:00 ET
Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
2019-11-05 12:00 ET
Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results
2019-10-28 12:00 ET
Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
2019-08-28 12:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences in September
2019-08-07 12:00 ET
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
2019-08-06 12:00 ET
Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference
2019-08-01 11:00 ET
Blueprint Medicines Reports Second Quarter 2019 Financial Results
2019-07-25 12:00 ET
Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
2019-07-18 20:01 ET
Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRa D842V Mutant GIST and Fourth-Line GIST
2019-06-14 12:45 ET
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
2019-05-29 20:00 ET
Blueprint Medicines to Present at Upcoming Investor Conferences in June
2019-05-02 12:00 ET
Blueprint Medicines to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
2019-04-02 20:01 ET
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
2019-03-29 00:40 ET
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
2019-03-05 13:01 ET
Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference
2019-02-26 12:00 ET
Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-19 13:00 ET
Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
2019-01-24 14:00 ET
Three Companies Using AI and Innovation to Lead Healthcare Sector

SEC forms

Show financial reports only

SEC form 10
2025-05-01 20:19 ET
Blueprint Medicines reported for 2025 q1
SEC form 8
2025-05-01 11:12 ET
Blueprint Medicines published news for 2025 q1
SEC form 8
2025-05-01 11:12 ET
Blueprint Medicines published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Blueprint Medicines published news for 2025 q1
SEC form 10
2025-02-13 17:09 ET
Blueprint Medicines reported for 2024 q4
SEC form 8
2025-02-13 07:34 ET
Blueprint Medicines published news for 2024 q4
SEC form 8
2025-02-13 07:34 ET
Blueprint Medicines published news for 2024 q4
SEC form 10
2025-02-13 00:00 ET
Blueprint Medicines published news for 2024 q4
SEC form 10
2024-10-30 16:27 ET
Blueprint Medicines reported for 2024 q3
SEC form 8
2024-10-30 07:07 ET
Blueprint Medicines published news for 2024 q3
SEC form 8
2024-10-30 07:07 ET
Blueprint Medicines published news for 2024 q3
SEC form 10
2024-10-30 00:00 ET
Blueprint Medicines published news for 2024 q3
SEC form 10
2024-08-01 16:48 ET
Blueprint Medicines published news for 2024 q2
SEC form 8
2024-08-01 07:29 ET
Blueprint Medicines published news for 2024 q2
SEC form 8
2024-08-01 07:29 ET
Blueprint Medicines reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Blueprint Medicines published news for 2024 q2
SEC form 10
2024-05-02 16:43 ET
Blueprint Medicines published news for 2024 q1
SEC form 8
2024-05-02 07:09 ET
Blueprint Medicines published news for 2024 q1
SEC form 8
2024-05-02 07:09 ET
Blueprint Medicines reported for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Blueprint Medicines published news for 2024 q1
SEC form 8
2024-02-15 00:00 ET
Blueprint Medicines published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Blueprint Medicines published news for 2023 q4
SEC form 10
2024-02-15 00:00 ET
Blueprint Medicines reported for 2023 q4
SEC form 10
2023-10-26 16:01 ET
Blueprint Medicines published news for 2023 q3
SEC form 8
2023-10-26 07:00 ET
Blueprint Medicines reported for 2023 q3
SEC form 10
2023-10-26 00:00 ET
Blueprint Medicines published news for 2023 q3
SEC form 10
2023-08-02 16:02 ET
Blueprint Medicines published news for 2023 q2
SEC form 6
2023-08-02 07:00 ET
Blueprint Medicines reported for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Blueprint Medicines published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Blueprint Medicines published news for 2023 q2
SEC form 6
2023-06-30 06:03 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-27 16:01 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:07 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:06 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:06 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:05 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:04 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:04 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:03 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:00 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-07 19:52 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-07 19:48 ET
Blueprint Medicines published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Blueprint Medicines published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Blueprint Medicines published news for 2023 q1
SEC form 8
2023-02-16 00:00 ET
Blueprint Medicines reported for 2022 q4
SEC form 10
2023-02-16 00:00 ET
Blueprint Medicines reported for 2022 q4
SEC form 10
2022-11-01 00:00 ET
Blueprint Medicines reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Blueprint Medicines published news for 2022 q3
SEC form 8
2022-08-02 00:00 ET
Blueprint Medicines reported for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Blueprint Medicines reported for 2022 q2
SEC form 8
2022-05-03 00:00 ET
Blueprint Medicines reported for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Blueprint Medicines reported for 2022 q1
SEC form 10
2022-02-17 00:00 ET
Blueprint Medicines published news for 2021 q4
SEC form 8
2022-02-16 00:00 ET
Blueprint Medicines published news for 2021 q4
SEC form 8
2021-10-28 00:00 ET
Blueprint Medicines published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
Blueprint Medicines published news for 2021 q3
SEC form 8
2021-07-29 00:00 ET
Blueprint Medicines published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Blueprint Medicines published news for 2021 q2
SEC form 8
2021-04-29 00:00 ET
Blueprint Medicines published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
Blueprint Medicines published news for 2021 q1